Phasebio Pharmaceuticals Inc(PHAS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAS Phasebio Pharmaceuticals Inc

Post-Market Trading 11-05 18:19:36 EST

0.0701

+0.0000

0.00%

High0.0701	Low0.0701	Vol0.00
Open0.0701	D1 Closing0.0701	Amplitude0.00%
Mkt Cap3.50M	Tradable Cap2.41M	Total Shares49.86M
T/O0.00	T/O Rate0.00%	Tradable Shares34.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PHAS","market":"US","secType":"STK","nameCN":"Phasebio Pharmaceuticals Inc","latestPrice":0.0701,"timestamp":1683316800000,"preClose":0.0701,"halted":0,"volume":0,"delay":0,"floatShares":34410934,"shares":49858116,"eps":-2.118926,"marketStatus":"Post-Market Trading","change":0,"latestTime":"11-05 18:19:36 EST","open":0.0701,"high":0.0701,"low":0.0701,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.118926,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1730854800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1539835200000,"exchange":"NASDAQ","adjPreClose":0.0701,"volumeRatio":0},"requestUrl":"/m/hq/s/PHAS/tweets","defaultTab":"tweets","newsList":[{"id":"2278788882","title":"PhaseBio announces Chapter 11 filing; plans to sell lead asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2278788882","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2278788882?lang=en_us&edition=fundamental","pubTime":"2022-10-24 20:59","pubTimestamp":1666616349,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172726837/image_172726837.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172726837/image_172726837.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/3894073-phas-stock-falls-on-plans-for-chapter-11-filing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","PHAS"],"gpt_icon":0},{"id":"2277724432","title":"PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code","url":"https://stock-news.laohu8.com/highlight/detail?id=2277724432","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2277724432?lang=en_us&edition=fundamental","pubTime":"2022-10-24 20:00","pubTimestamp":1666612800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/k5P4Xk1Y.9Xq0cSaZYLxrQ--~B/aD0xMjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/pmVEdvKQG_B9w0IqN1tmFA--~B/aD0xMjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d641e2e04146b742f5be8735d6ecde92","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/k5P4Xk1Y.9Xq0cSaZYLxrQ--~B/aD0xMjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/pmVEdvKQG_B9w0IqN1tmFA--~B/aD0xMjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d641e2e04146b742f5be8735d6ecde92"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phasebio-plans-near-term-sale-120000640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","TERN","BK4191","BK4007","BK4139","PHAS","CRCT"],"gpt_icon":0},{"id":"2271173619","title":"PhaseBio Pharmaceuticals Cut to Hold From Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2271173619","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2271173619?lang=en_us&edition=fundamental","pubTime":"2022-09-29 00:46","pubTimestamp":1664383560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAS","BK4139"],"gpt_icon":0},{"id":"2270951784","title":"PhaseBio Might Have To Return Global Rights To Its Lead Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2270951784","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2270951784?lang=en_us&edition=fundamental","pubTime":"2022-09-28 21:06","pubTimestamp":1664370380,"startTime":"0","endTime":"0","summary":"\n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/22/09/29049003/phasebio-might-have-to-return-global-rights-to-its-lead-program","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQ","BK4139","AZN","PHAS","QID","SQQQ","PSQ","MNQmain","BK4568","TQQQ","QLD","BK4007",".IXIC","NQmain"],"gpt_icon":0},{"id":"2270807788","title":"PhaseBio Pharmaceuticals Cut to Market Perform From Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2270807788","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2270807788?lang=en_us&edition=fundamental","pubTime":"2022-09-28 18:23","pubTimestamp":1664360580,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PHAS"],"gpt_icon":0},{"id":"2249536723","title":"BRIEF-Phasebio Pharmaceuticals Says Received A Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2249536723","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2249536723?lang=en_us&edition=fundamental","pubTime":"2022-07-06 04:47","pubTimestamp":1657054052,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4124","SMP","PHAS"],"gpt_icon":0},{"id":"2235400126","title":"PhaseBio Pharmaceuticals: Q1 Earnings Insights","url":"https://stock-news.laohu8.com/highlight/detail?id=2235400126","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2235400126?lang=en_us&edition=fundamental","pubTime":"2022-05-16 19:54","pubTimestamp":1652702076,"startTime":"0","endTime":"0","summary":" \n\nPhaseBio Pharmaceuticals (NASDAQ:PHAS) reported its Q1 earnings results on Monday, May 16, 2022 at 06:00 AM.\n\nHere&#39;s what investors need to know about the announcement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/22/05/27216239/phasebio-pharmaceuticals-q1-earnings-insights","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAS"],"gpt_icon":0},{"id":"2235401264","title":"PhaseBio to seek FDA approval for clotting agent in 4Q 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2235401264","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2235401264?lang=en_us&edition=fundamental","pubTime":"2022-05-16 19:50","pubTimestamp":1652701830,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/3839018-phas-stock-in-focus-on-plans-to-seek-fda-approval-for-clotting-agent","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["PHAS","BK4139"],"gpt_icon":0},{"id":"2235091294","title":"PhaseBio Pharmaceuticals GAAP EPS of -$0.23 beats by $0.43","url":"https://stock-news.laohu8.com/highlight/detail?id=2235091294","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2235091294?lang=en_us&edition=fundamental","pubTime":"2022-05-16 19:25","pubTimestamp":1652700340,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/3839000-phasebio-pharmaceuticals-gaap-eps-of-0_23-beats-0_43","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","PHAS"],"gpt_icon":0},{"id":"2235289694","title":"PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2235289694","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2235289694?lang=en_us&edition=fundamental","pubTime":"2022-05-16 19:15","pubTimestamp":1652699711,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R8B4awdI246EbZIDm2Hv5Q--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/t6.OdXEVKQihFo9otNenfg--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R8B4awdI246EbZIDm2Hv5Q--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/t6.OdXEVKQihFo9otNenfg--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phasebio-pharmaceuticals-phas-reports-q1-111511070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PTN","PHAS"],"gpt_icon":0},{"id":"2235062494","title":"PhaseBio Pharmaceuticals Q1 EPS $(0.23) Up From $(0.87) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2235062494","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2235062494?lang=en_us&edition=fundamental","pubTime":"2022-05-16 18:07","pubTimestamp":1652695658,"startTime":"0","endTime":"0","summary":"PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported quarterly losses of $(0.23) per share. This is a 73.56 percent increase over losses of $(0.87) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/22/05/27213920/phasebio-pharmaceuticals-q1-eps-0-23-up-from-0-87-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAS"],"gpt_icon":0},{"id":"2235409324","title":"Phasebio Pharmaceuticals Reports Q1 Loss Of 23 Cents Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2235409324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2235409324?lang=en_us&edition=fundamental","pubTime":"2022-05-16 18:03","pubTimestamp":1652695380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAS","BK4023","BK4007","APR","LABP","BK4196","BK4082","BK4139","LHDX","ONTF","SANA","CGEM"],"gpt_icon":0},{"id":"2235409847","title":"PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2235409847","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2235409847?lang=en_us&edition=fundamental","pubTime":"2022-05-16 18:00","pubTimestamp":1652695200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SfBmnRTxtjdzUXe9RZLXsA--~B/aD0xMjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/2xuigDf2755YGYp3KI4ugw--~B/aD0xMjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e22c30862798039805a873c1999897bb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SfBmnRTxtjdzUXe9RZLXsA--~B/aD0xMjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/2xuigDf2755YGYp3KI4ugw--~B/aD0xMjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e22c30862798039805a873c1999897bb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phasebio-pharmaceuticals-reports-first-quarter-100000165.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4167","FWRG","TERN","BK4139","BK4539","ALVU","BK4191","BK4209","CRCT","HCTI","OLPX","BK4007","BK4183","PHAS"],"gpt_icon":0},{"id":"2235409840","title":"PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2235409840","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2235409840?lang=en_us&edition=fundamental","pubTime":"2022-05-16 18:00","pubTimestamp":1652695200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0etrSsv_oS3OKmt8LY6Zcw--~B/aD0xMjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/7gjM7TSNl4Z2ay0kmU2xvg--~B/aD0xMjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/be5f96adfdd93d0e1aff8f2d48ee6b17","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0etrSsv_oS3OKmt8LY6Zcw--~B/aD0xMjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/7gjM7TSNl4Z2ay0kmU2xvg--~B/aD0xMjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/be5f96adfdd93d0e1aff8f2d48ee6b17"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phasebio-announces-successful-pre-bla-100000745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4167","FWRG","TERN","BK4139","BK4539","ALVU","BK4191","BK4209","CRCT","HCTI","OLPX","BK4007","BK4183","PHAS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.phasebio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.040973},{"month":2,"riseRate":0.2,"avgChangeRate":-0.124917},{"month":3,"riseRate":0.4,"avgChangeRate":0.371332},{"month":4,"riseRate":0.4,"avgChangeRate":0.06721},{"month":5,"riseRate":0.4,"avgChangeRate":0.025307},{"month":6,"riseRate":0.5,"avgChangeRate":-0.032346},{"month":7,"riseRate":0.25,"avgChangeRate":0.068841},{"month":8,"riseRate":0.25,"avgChangeRate":-0.014805},{"month":9,"riseRate":0,"avgChangeRate":-0.37053},{"month":10,"riseRate":0.25,"avgChangeRate":-0.110027},{"month":11,"riseRate":0.2,"avgChangeRate":-0.204981},{"month":12,"riseRate":0.6,"avgChangeRate":0.219493}],"exchange":"NASDAQ","name":"Phasebio Pharmaceuticals Inc","nameEN":"Phasebio Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phasebio Pharmaceuticals Inc(PHAS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Phasebio Pharmaceuticals Inc(PHAS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Phasebio Pharmaceuticals Inc,PHAS,Phasebio Pharmaceuticals Inc股票,Phasebio Pharmaceuticals Inc股票老虎,Phasebio Pharmaceuticals Inc股票老虎国际,Phasebio Pharmaceuticals Inc行情,Phasebio Pharmaceuticals Inc股票行情,Phasebio Pharmaceuticals Inc股价,Phasebio Pharmaceuticals Inc股市,Phasebio Pharmaceuticals Inc股票价格,Phasebio Pharmaceuticals Inc股票交易,Phasebio Pharmaceuticals Inc股票购买,Phasebio Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phasebio Pharmaceuticals Inc(PHAS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Phasebio Pharmaceuticals Inc(PHAS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}